Multi-stage delivery nano-particle systems for therapeutic applications

Biochimica et Biophysica Acta - General Subjects

Volumn 1810, Issue 3, 2011, Pages 317-329

  Serda, Rita E ^a   Godin, Biana ^a   Blanco, Elvin ^a   Chiappini, Ciro ^b   Ferrari, Mauro ^a,b,c,d  

^a UNIVERSITY OF TEXAS   (United States)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Rice University   (United States)

Author keywords

Drug delivery; Microparticle; Multi stage vectors; Nanoparticle; Porous silicon

Indexed keywords

DOXORUBICIN; LIPOSOME; NANOPARTICLE; OPSONIN; QUANTUM DOT; SILICON; SINGLE WALLED NANOTUBE; VASCULOTROPIN 165;

BINDING AFFINITY; BIOCOMPATIBILITY; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL STRUCTURE; CELL VIABILITY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GEOMETRY; IC 50; IMAGING; IN VIVO STUDY; INTERNALIZATION; MACROPHAGE; MEMBRANE TRANSPORT; MITOSIS; NANODEVICE; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; TAXONOMY; TUMOR XENOGRAFT;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; POROSITY; SILICON;

EID: 79551575238     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2010.05.004     Document Type: Review

References (89)

1. M. Ferrari Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 2005 161 171
2. T. Theis, D. Parr, P. Binks, J. Ying, K.E. Drexler, E. Schepers, K. Mullis, C. Bai, J.J. Boland, R. Langer, P. Dobson, C.N. Rao, and M. Ferrari nan'o.tech.nol'o.gy n Nat. Nanotechnol. 1 2006 8 10
3. K. Riehemann, S.W. Schneider, T.A. Luger, B. Godin, M. Ferrari, and H. Fuchs Nanomedicine-challenge and perspectives Angew. Chem. Int. Ed Engl. 48 2009 872 897
4. R.K. Jain Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J. Natl Cancer Inst. 81 1989 570 576
5. R.K. Jain Transport of molecules, particles, and cells in solid tumors Annu. Rev. Biomed. Eng. 1 1999 241 263
6. J. Sakamoto, A. Annapragada, P. Decuzzi, and M. Ferrari Antibiological barrier nanovector technology for cancer applications Expert Opin. Drug Deliv. 4 2007 359 369
7. M. Ferrari Nanovector therapeutics Curr. Opin. Chem. Biol. 9 2005 343 346
8. M. Ferrari, Frontiers in Cancer Nanomedicine: Transport Oncophysics and Logic-Embedded Vectors, Trends in Biotechnology (in press).
9. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277
10. S.M. Moghimi, and S.S. Davis Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection Crit. Rev. Ther. Drug Carrier Syst. 11 1994 31 59
11. D. Mehta, and A.B. Malik Signaling mechanisms regulating endothelial permeability Physiol. Rev. 86 2006 279 367
12. M. Stohrer, Y. Boucher, M. Stangassinger, and R.K. Jain Oncotic pressure in solid tumors is elevated Cancer Res. 60 2000 4251 4255
13. J.R. Less, M.C. Posner, Y. Boucher, D. Borochovitz, N. Wolmark, and R.K. Jain Interstitial hypertension in human breast and colorectal tumors Cancer Res. 52 1992 6371 6374
14. V.P. Torchilin Recent approaches to intracellular delivery of drugs and DNA and organelle targeting Annu. Rev. Biomed. Eng. 8 2006 343 375
15. S. Majumdar, and A.K. Mitra Chemical modification and formulation approaches to elevated drug transport across cell membranes Expert Opin. Drug Deliv. 3 2006 511 527
16. S.D. Undevia, G. Gomez-Abuin, and M.J. Ratain Pharmacokinetic variability of anticancer agents Nat. Rev. 5 2005 447 458
17. P. Canal, E. Gamelin, G. Vassal, and J. Robert Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy Pathol. Oncol. Res. 4 1998 171 178
18. V. Wagner, A. Dullaart, A.K. Bock, and A. Zweck The emerging nanomedicine landscape Nat. Biotechnol. 24 2006 1211 1217
19. W.R. Sanhai, J.H. Sakamoto, R. Canady, and M. Ferrari Seven challenges for nanomedicine Nat. Nanotechnol. 3 2008 242 244
20. J.R. Heath, and M.E. Davis Nanotechnology and cancer Annu. Rev. Med. 59 2008 251 265
21. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363 1380
22. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
23. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
24. J.S. Hrkach, M.T. Peracchia, A. Domb, N. Lotan, and R. Langer Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy Biomaterials 18 1997 27 30
25. J. Senior, C. Delgado, D. Fisher, C. Tilcock, and G. Gregoriadis Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim. Biophys. Acta 1062 1991 77 82
26. D.E. Owens III, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
27. C.C. Lee, J.A. MacKay, J.M. Frechet, and F.C. Szoka Designing dendrimers for biological applications Nat. Biotechnol. 23 2005 1517 1526
28. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
29. L. Brannon-Peppas, and J.O. Blanchette Nanoparticle and targeted systems for cancer therapy Adv. Drug Deliv. Rev. 56 2004 1649 1659
30. A.A. Kale, and V.P. Torchilin "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes J. Liposome Res. 17 2007 197 203
31. O.C. Farokhzad, and R. Langer Impact of nanotechnology on drug delivery ACS Nano 3 2009 16 20
32. G.R. Souza, F.I. Staquicini, D.R. Christianson, M.G. Ozawa, J.H. Miller, R. Pasqualini, and W. Arap Combinatorial targeting and nanotechnology applications Biomed Microdevices 2009
33. M. Juweid, R. Neumann, C. Paik, M.J. Perez-Bacete, J. Sato, W. van Osdol, and J.N. Weinstein Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier Cancer Res. 52 1992 5144 5153
34. G.R. Souza, D.R. Christianson, F.I. Staquicini, M.G. Ozawa, E.Y. Snyder, R.L. Sidman, J.H. Miller, W. Arap, and R. Pasqualini Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents Proc. Natl. Acad. Sci. U. S. A. 103 2006 1215 1220
35. S. Sengupta, D. Eavarone, I. Capila, G. Zhao, N. Watson, T. Kiziltepe, and R. Sasisekharan Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 2005 568 572
36. A.M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, and H. He Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small 2009
37. E. Tasciotti, X. Liu, R. Bhavane, K. Plant, A.D. Leonard, B.K. Price, M.M. Cheng, P. Decuzzi, J.M. Tour, F. Robertson, and M. Ferrari Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications Nat. Nanotechnol. 3 2008 151 157
38. P. Decuzzi, and M. Ferrari Design maps for nanoparticles targeting the diseased microvasculature Biomaterials 29 2008 377 384
39. P. Decuzzi, and M. Ferrari Modulating cellular adhesion through nanotopography Biomaterials 31 2010 173 179
40. F. Gentile, C. Chiappini, D. Fine, R.C. Bhavane, M.S. Peluccio, M.M. Cheng, X. Liu, M. Ferrari, and P. Decuzzi The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows J. Biomech. 41 2008 2312 2318
41. F. Gentile, A. Curcio, C. Indolfi, M. Ferrari, and P. Decuzzi The margination propensity of spherical particles for vascular targeting in the microcirculation J. Nanobiotechnol. 6 2008 9
42. S.Y. Lee, M. Ferrari, and P. Decuzzi Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows Nanotechnology 20 2009 495101
43. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. Ferrari Size and shape effects in the biodistribution of intravascularly injected particles J. Control. Release 1 2009
44. M.L. Tanaka, P.E. Vivas-Mejia, R. Nieves-Alicea, A.P. Mann, E. Mora, H. Han, M.M.K. Shahzad, X. Liu, R. Bhavane, J. Gu, J.R. Fakhoury, C. Chiappini, C. Lu, K. Matsuo, B. Godin, R.L. Stone, A.M. Nick, G. Lopez-Berestein, A.K. Sood, and M. Ferrari Sustained siRNA delivery by mesoporous silicon particles Cancer Res. forthcoming 2010
45. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464
46. R.L. Hong, C.J. Huang, Y.L. Tseng, V.F. Pang, S.T. Chen, J.J. Liu, and F.H. Chang Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5 1999 3645 3652
47. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237
48. R.E. Serda, C. Chiappini, D. Fine, E. Tasciotti, M. Ferrari, Porous silicon particles for imaging and therapy of cancer, Nanostructured Oxides, C.S.S.R. Kumar Ed., Wiley VCH Verlag GmbH&Co. 2 (2009) 357-398.
49. C. Chiappini, E. Tasciotti, J.R. Fakhoury, D. Fine, L. Pullan, Y.C. Wang, L. Fu, X. Liu, and M. Ferrari Tailored porous silicon microparticles: fabrication and properties Chemphyschem. 11 2010 1029 1035
50. R. Herino, G. Bomchil, K. Barla, and C. Bertand Porosity and pore size distributions of porous silicon layers J. Eectrochem. Soc. 134 1987 1994 2000
51. X.G. Zhang Morphology and formation mechanisms of porous silicon J. Electrochem. Soc. 151 2004 C69 C80
52. X. Zhang, C. Zhang, H. Guo, W. Huang, T. Polenova, L.C. Francesconi, and D.L. Akins Optical spectra of a novel polyoxometalate occluded within modified MCM-41 J. Phys. Chem. B 109 2005 19156 19160
53. S. Boujday, J. Blanchard, R. Villanneau, J.M. Krafft, C. Geantet, C. Louis, M. Breysse, and A. Proust Polyoxomolybdate-stabilized Ru(0) nanoparticles deposited on mesoporous silica as catalysts for aromatic hydrogenation Chemphyschem 8 2007 2636 2642
54. R. Mellaerts, J.A. Jammaer, M. Van Speybroeck, H. Chen, J. Van Humbeeck, P. Augustijns, G. Van den Mooter, and J.A. Martens Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen Langmuir 24 2008 8651 8659
55. F. Winau, O. Westphal, and R. Winau Paul Ehrlich-in search of the magic bullet Microbes Infect. 6 2004 786 789
56. R. Pasqualini, E. Koivunen, and E. Ruoslahti Alpha v integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15 1997 542 546
57. P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26 2009 235 243
58. C. Khemtong, C.W. Kessinger, J. Ren, E.A. Bey, S.G. Yang, J.S. Guthi, D.A. Boothman, A.D. Sherry, and J. Gao In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles Cancer Res. 69 2009 1651 1658
59. V. Thiviyanathan, A.D. Somasunderam, and D.G. Gorenstein Combinatorial selection and delivery of thioaptamers Biochem. Soc. Trans. 35 2007 50 52
60. T.A. Olson, D. Mohanraj, S. Roy, and S. Ramakrishnan Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate Int. J. Cancer 73 1997 865 870
61. J.D. Hood, M. Bednarski, R. Frausto, S. Guccione, R.A. Reisfeld, R. Xiang, and D.A. Cheresh Tumor regression by targeted gene delivery to the neovasculature Science 296 2002 2404 2407
62. S.D. Weitman, A.G. Weinberg, L.R. Coney, V.R. Zurawski, D.S. Jennings, and B.A. Kamen Cellular-localization of the folate receptor-potential role in drug toxicity and folate homeostasis Cancer Res. 52 1992 6708 6711
63. H.S. Yoo, and T.G. Park Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate J. Control. Release 100 2004 247 256
64. J.R. Wands, and H.E. Blum Primary hepatocellular carcinoma N Engl J. Med. 325 1991 729 731
65. Y.I. Jeong, S.J. Seo, I.K. Park, H.C. Lee, I.C. Kang, T. Akaike, and C.S. Cho Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety Int. J. Pharm. 296 2005 151 161
66. A. Tomadoni, D. Lombardo, and R. Wainstein Trastuzumab in the treatment of advanced breast cancer. Our single-center experience and spotlights of the latest national consensus meeting Medicina (B Aires) 64 2004 20 24
67. L.B. Carpin, L.R. Bickford, G. Agollah, T.K. Yu, R. Schiff, Y. Li, and R.A. Drezek Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells Breast Cancer Res. Treat. 2010
68. S. Wagner, F. Rothweiler, M.G. Anhorn, D. Sauer, I. Riemann, E.C. Weiss, A. Katsen-Globa, M. Michaelis, J. Cinatl Jr., D. Schwartz, J. Kreuter, H. von Briesen, and K. Langer Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles Biomaterials 31 2010 2388 2398
69. E.V. Finlayson, P.P. Goodney, and J.D. Birkmeyer Hospital volume and operative mortality in cancer surgery: a national study Arch. Surg. 138 2003 721 725 discussion 726
70. M. Elshaikh, M. Ljungman, R. Ten Haken, and A.S. Lichter Advances in radiation oncology Annu. Rev. Med. 2005
71. A.A. Gabizon Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy Cancer Invest 19 2001 424 436
72. N. Kamaly, T. Kalber, A. Ahmad, M.H. Oliver, P.W. So, A.H. Herlihy, J.D. Bell, M.R. Jorgensen, and A.D. Miller Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging Bioconjug. Chem. 19 2008 118 129
73. S. Zalipsky, M. Saad, R. Kiwan, E. Ber, N. Yu, and T. Minko Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action J. Drug Target. 15 2007 518 530
74. D.J. Booser, F.J. Esteva, E. Rivera, V. Valero, L. Esparza-Guerra, W. Priebe, and G.N. Hortobagyi Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer Cancer Chemother. Pharmacol. 50 2002 6 8 (Pubitemid 34743989)
75. Y. Zou, W. Priebe, and R. Perez-Soler Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size Cancer Chemother. Pharmacol. 39 1996 103 108
76. L. Gros, H. Ringsdorf, and H. Schupp Polymeric anti-tumor agents on a molecular and on a cellular-level Angew Chem Int Edit 20 1981 305 325
77. R. Savic, L. Luo, A. Eisenberg, and D. Maysinger Micellar nanocontainers distribute to defined cytoplasmic organelles Science 300 2003 615 618
78. Y. Matsumura, and K. Kataoka Preclinical and clinical studies of anticancer agent-incorporating polymer micelles Cancer Sci. 100 2009 572 579
79. T. Nakanishi, S. Fukushima, K. Okamoto, M. Suzuki, Y. Matsumura, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Development of the polymer micelle carrier system for doxorubicin J. Control. Release 74 2001 295 302
80. T. Satomi, Y. Nagasaki, H. Kobayashi, H. Otsuka, and K. Kataoka Density control of poly(ethylene glycol) layer to regulate cellular attachment Langmuir 23 2007 6698 6703
81. Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. Ueno, M. Ikeda, and N. Watanabe Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781
82. P.H. Wiernik, E.L. Schwartz, J.J. Strauman, J.P. Dutcher, R.B. Lipton, and E. Paietta Phase I clinical and pharmacokinetic study of taxol Cancer Res. 47 1987 2486 2493
83. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, and Y.J. Bang Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716
84. L.R. Hirsch, R.J. Stafford, J.A. Bankson, S.R. Sershen, B. Rivera, R.E. Price, J.D. Hazle, N.J. Halas, and J.L. West Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance Proc. Natl. Acad. Sci. U. S. A. 100 2003 13549 13554
85. C. Loo, A. Lin, L. Hirsch, M.H. Lee, J. Barton, N. Halas, J. West, and R. Drezek Nanoshell-enabled photonics-based imaging and therapy of cancer Technol. Cancer Res. Treat. 3 2004 33 40
86. R.E. Serda, J. Gu, R.C. Bhavane, X. Liu, C. Chiappini, P. Decuzzi, and M. Ferrari The association of silicon microparticles with endothelial cells in drug delivery to the vasculature Biomaterials 30 2009 2440 2448
87. R.E. Serda, S. Ferrati, B. Godin, E. Tasciotti, X. Liu, and M. Ferrari Mitotic partitioning of silicon microparticles Nanoscale 2 2009 173 288
88. R.E. Serda, J. Gu, J.K. Burks, K. Ferrari, C. Ferrari, and M. Ferrari Quantitative mechanics of endothelial phagocytosis of silicon microparticles Cytom. A 75 2009 752 760
89. J.H. Sakamoto, A.L. van de Ven, B. Godin, E. Blanco, R.E. Serda, A. Grattoni, A. Ziemys, A. Bouamrani, T. Hu, S.I. Ranganathan, E. De Rosa, J.O. Martinez, C.A. Smid, R.M. Buchanan, S.Y. Lee, S. Srinivasan, M. Landry, A. Meyn, E. Tasciotti, X. Liu, P. Decuzzi, and M. Ferrari Enabling individualized therapy through nanotechnology Pharmacol. Res. 2010